Heron Therapeutics (HRTX) to Release Quarterly Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is anticipated to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $2.39 on Friday. The firm has a market capitalization of $364.07 million, a PE ratio of -13.28 and a beta of 1.55. The firm’s 50-day moving average is $1.77 and its two-hundred day moving average is $1.73. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on HRTX shares. Needham & Company LLC restated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.